Transdermal Rotigotine User Surveillance Study (TRUST)

UCB

Status: Completed

Conditions: Idiopathic Parkinson Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT00599339

SP0854

Details and patient eligibility

About

This study will be conducted in an observational multiple-cohort design aimed at acquiring clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD) will be enrolled.

Full description

All patients attending the physician and fulfilling the eligibility criteria are included.

Enrollment: 2,195 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with idiopathic early-stage Parkinson's Disease requiring dopaminergic monotherapy (rotigotine, other dopamine agonists or levodopa) at study onset
• Patients with advanced-stage Parkinson's Disease requiring dopaminergic therapy with levodopa in combination with rotigotine or other dopamine agonists at study onset

Exclusion criteria

• Patients who are unable to comply with study requirements

Trial design

2,195 participants in 5 patient groups

Neupro

Description:

Neupro at study onset

Dopamine Agonist

Description:

Other Dopamine-Agonist at study onset

L-Dopa

Description:

L-Dopa

Neupro + L-Dopa

Description:

Neupro in combination with L-Dopa at study onset

Dopamine Agonist + L-Dopa

Description:

Other Dopamine Agonist in combination with L-Dopa at study onset